US2003082829A1PendingUtilityA1
Novel 8.4 kDa immunophilin
Priority: Aug 23, 2000Filed: Feb 13, 2002Published: May 1, 2003
Est. expiryAug 23, 2020(expired)· nominal 20-yr term from priority
Inventors:Steven J. Soldin
G01N 33/9493Y10S436/815
45
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
We have identified and purified to homogeneity from lymphatic tissues a novel 8.4 kDa immunophilin that specifically and avidly binds the immunosuppressant drugs FK-506 (Kd=0.8 nM) and rapamycin (Kd=0.08 nM) and their pharmacologically active metabolites and derivatives, but does not bind cyclosporin A. The isolated 8.4 kDa protein was analyzed for partial amino acid sequence, molecular weight, binding constants, binding specificity, biochemical aspects, and utility as the protein binding reagent in binding assays for immunosuppressant drugs in fluid samples, including patient blood.
Claims
exact text as granted — not AI-modifiedI claim:
1 . An immunophilin, comprising a protein with the following properties:
(i) a protein of 8.4 kDa mass; (ii) isolated from the soluble cytoplasm of lymphoid tissues; (iii) the N-terminal first 23 amino acid sequence is: MET GLN ILE PHE VAL LYS THR LEU THR Seq. ID No. 1 GLY LYS THR ILE THR LEU GLU VAL GLU PRO SER ASP THR ILE and, (iv) capable of specifically binding FK-506, rapamycin, or pharmacologically active metabolites or derivatives thereof, but not cyclosporins.
2 . An immunophilin according to claim 1 , wherein said protein exhibits retention times on HPLC identical to that of authentic ubiquitin.
3 . An immunophilin according to claim 1 , wherein said protein migrates on SDS-PAGE electrophoresis plates identically to authentic ubiquitin.
4 . An immunophilin according to claim 1 , wherein said protein exhibits a Kd of about 0.8 nM for FK-506 and 0.08 nM for rapamycin.
5 . An immunophilin according to claim 1 , wherein said protein has a Hill plot value of about unity.
6 . An immunophilin according to claim 1 , wherein said protein, and when complexed to FK-506, inhibits calcineurin phosphatase activity.
7 . A recombinant 8.4 kDa immunophilin with the properties exhibited by the immunophilin according to claim 1 .
8 . A mercantile kit for the determination of immunosuppressant drugs FK-506, rapamycin and pharmacologically active metabolites and derivatives thereof in a fluid sample, comprising, in separate compartments: said isolated 8.4 kDa immunophilin; optionally, one or more of unlabeled said immunosuppressant drugs or pharmacologically-active metabolites or derivatives thereof; and, optionally, one or more labeled said immunosuppressant drugs or pharmacologically-active metabolites or derivatives thereof.Join the waitlist — get patent alerts
Track US2003082829A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.